Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Myeloma, Newly Diagnosed”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT06045806
What this trial is testing

Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Who this might be right for
Multiple Myeloma
Celgene 79
Early research (Phase 1)Ended earlyNCT04892264
What this trial is testing

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Who this might be right for
Plasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Mayo Clinic 5
Large-scale testing (Phase 3)Active Not RecruitingNCT04751877
What this trial is testing

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

Who this might be right for
Multiple MyelomaMyeloma
Poitiers University Hospital 270
Very early researchLooking for participantsNCT06142396
What this trial is testing

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Who this might be right for
Multiple MyelomaRenal Failure
Augusta University 30
Testing effectiveness (Phase 2)WithdrawnNCT04223661
What this trial is testing

Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

Who this might be right for
Multiple Myeloma
Attaya Suvannasankha
Testing effectiveness (Phase 2)Study completedNCT01852799
What this trial is testing

PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT03004287
What this trial is testing

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Who this might be right for
Multiple Myeloma
University of Arkansas 50
Early research (Phase 1)Study completedNCT03311828
What this trial is testing

Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaPlasma Cell MyelomaSecondary Amyloidosis
City of Hope Medical Center 12
Large-scale testing (Phase 3)Study completedNCT00551928
What this trial is testing

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

Who this might be right for
Multiple MyelomaNewly Diagnosed Patients
Fondazione EMN Italy Onlus 402
Large-scale testing (Phase 3)Not Yet RecruitingNCT06895512
What this trial is testing

Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

Who this might be right for
Newly Diagnosed Multiple Myeloma
Shanghai Henlius Biotech 386
Early research (Phase 1)Active Not RecruitingNCT02334865
What this trial is testing

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Who this might be right for
Partial Response of Multiple Myeloma or Plasma Cell LeukemiaPlasma Cell Myeloma
Roswell Park Cancer Institute 18
Large-scale testing (Phase 3)Study completedNCT00097981
What this trial is testing

Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 225
Large-scale testing (Phase 3)Study completedNCT03402295
What this trial is testing

Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation

Who this might be right for
Multiple MyelomaEffects of Chemotherapy
Grupo de Estudos Multicentricos em Onco-Hematologia 311
Testing effectiveness (Phase 2)Looking for participantsNCT07409454
What this trial is testing

MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 20
Testing effectiveness (Phase 2)Study completedNCT02224729
What this trial is testing

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 24
Large-scale testing (Phase 3)Study completedNCT01345019
What this trial is testing

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Who this might be right for
CancerHematologic MalignanciesMultiple Myeloma+3 more
Amgen 1,718
Testing effectiveness (Phase 2)Study completedNCT00317811
What this trial is testing

Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Oncotherapeutics 35
Testing effectiveness (Phase 2)Looking for participantsNCT07106736
What this trial is testing

MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China 60
Testing effectiveness (Phase 2)Study completedNCT01376401
What this trial is testing

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 60
Testing effectiveness (Phase 2)UnknownNCT03695744
What this trial is testing

Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

Who this might be right for
Multiple MyelomaMyeloma
Singapore General Hospital 27
Next Page